BM Shockwave Devices Clinical Study in Coronary Calcified Lesions

Recruiting now · Not applicable

Conditions studied: Coronary Artery Disease

In brief

This clinical trial is a prospective, multicenter, single-arm, target-value study to verify the safety and efficacy of BM coronary shockwave devices for the treatment of coronary calcification lesions.

Key facts

Study ID

NCT07010094

Run by

BrosMed Medical Co., Ltd

People needed

198

Starts

2025-06-27

Expected to finish

2026-12-31

Last updated by the study team

2025-07-25

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• General inclusion criteria:
• Age 18-85 years, male or female;
• Patients with evidence of asymptomatic ischemia, stable or unstable angina, or old myocardial infarction;
• Patient is able and willing to comply with all assessments in the study.
• Angiography inclusion criteria:
• The target lesion is a de novo, in-situ coronary artery lesion;
• The target lesion length is ≤40 mm, and the target lesion reference vessel diameter is 2.0-4.0 mm (visual estimation);
• The target lesion diameter stenosis is visually estimated to be ≥70%, or <70% but ≥50% with evidence of ischemia;
• Clear high-density calcification shadows are visible both during cardiac contraction and at rest;
• Target vessel TIMI flow grade 3 prior to use of the investigational device (pre-dilatation is permitted);
• The target lesion is the only calcified lesion to be treated with shock wave therapy in this session; if non-target lesions are present, they must be successfully treated prior to the target lesion;
• Patients suitable for treatment with metal stent implantation.

You may not qualify if…

• General exclusion criteria:
• ST-segment elevation myocardial infarction within 3 days prior to the procedure;
• Use of rotational atherectomy or special balloons (chocolate balloon, scoring balloon, cutting balloon, etc.) for lesion pretreatment;
• New York Heart Association (NYHA) functional class III or IV;
• Target lesion expected to require full biodegradable scaffold implantation, drug-eluting balloon dilation, or percutaneous transluminal coronary angioplasty (PTCA) treatment;
• Uncontrolled severe hypertension (persistent: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg);
• Severe liver or kidney dysfunction, with transaminase levels exceeding three times the upper limit of normal, serum creatinine >2.5 mg/dL (221 μmol/L), or chronic kidney failure requiring long-term dialysis;
• Platelet count <60 × 10⁹/L;
• Stroke within the past 6 months prior to enrollment, excluding transient ischemic attack (TIA) and lacunar infarction;
• Active peptic ulcer or history of upper gastrointestinal bleeding within the past 6 months prior to enrollment;
• Known allergy to heparin, contrast agents, aspirin, clopidogrel, or anesthetics;
• Patients with a life expectancy of less than 12 months due to severe medical conditions;
• Patients who have participated in other drug or device clinical trials and failed to meet the primary endpoint;
• Pregnant or breastfeeding women;
• Patients deemed by the investigator to have poor compliance and unable to complete the study according to the protocol.
• Contrast exclusion criteria:
• The target lesion and non-target lesion are in the same vascular branch;
• The target lesion is at the origin (LAD, LCX, or RCA, within 5 mm of the origin) or an unprotected left main lesion;
• A stent has been implanted within 10 mm of the proximal or distal end of the target lesion;
• The target lesion has an unprotected branch vessel with a diameter of 2.5 mm or greater;
• The target lesion is located distal to the saphenous vein or LIMA (left internal mammary artery)/RIMA (right internal mammary artery) bypass graft;
• An aneurysm is present within 10 mm of the target lesion;
• Contrast imaging confirms the presence of an NHLBI classification D-F type arterial dissection at the target lesion prior to the use of the investigational device;
• The target lesion has definite thrombus formation;
• The investigator determines that the target lesion is not suitable for vascular dilation in the patient.

Where it is running

• Xiamen University Affiliated Cardiovascular Hospital — Fujian, Xiamen, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.